PacBio Cuts FY26 Revenue Guidance Again; Cash Burn Persists

What happened

Pacific Biosciences reported mixed Q3 results with revenue beating lowered estimates but gross margins declining, prompting management to trim its FY2026 sales forecast yet again. The guidance cut reflects weaker-than-expected demand, likely driven by continued softness in Revio placements and slower Vega adoption than needed to offset funding-driven headwinds. The company’s cash burn remains substantial, with cash and investments falling from $389.9 million at end-2024 to $298.7 million at end-Q3 2025, and the new guidance implies ongoing operating cash outflows. This development aligns with the bear scenario in our prior report, where Vega placements fall below 30 per quarter and revenue stagnates near $165 million, pushing the stock toward the $1.10 implied value. The balance sheet continues to weaken, raising the risk of dilutive financing before utilization and margins stabilize.

Implication

The stock is likely to face continued pressure as the market reprices for lower revenue growth and extended cash burn. The prior base case of FY2026 revenue reaching ~$172 million now appears optimistic, and the bear case (revenue near $165 million) has gained probability. Our attractive entry point of $1.40 may be deferred until Q1–Q2 2026 data confirm that Vega placements sustain above 30 units per quarter and gross margin expansion tracks at least 200 basis points. Without such evidence, the risk of dilutive financing increases with each quarter of elevated cash burn, potentially driving the stock toward the bear-case implied value of $1.10. Investors should monitor quarterly placement prints, China commercialization metrics, and any signs of consumables pull-through stabilization before reconsidering the name.

Thesis delta

The investment thesis shifts from wait-and-see to more defensive: the guidance cut suggests the base case is eroding and the bear case (revenue near $165M, Vega placements below 30/quarter) becomes more likely. Attractive entry at $1.40 may be temporarily suspended until Q1–Q2 2026 data confirm stabilization.